eastpharma - april 08.ppt [uyumluluk modu] · eastpharma at a glance a leading branded generic...
TRANSCRIPT
APRIL 2008
PHILIPP HAAS – CHAIRMANIDIL BORA – IR MANAGER
This presentation has been prepared by EastPharma Ltd (the “Company”) solely for its use at the presentation to investors to be made in April 2007. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.This document is not a prospectus. This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall any part of it nor the fact of its distribution form part of or be relied on in connection with any contract or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of the Company.This presentation is being supplied to you solely for your information. This presentation and its contents are confidential and may not be further copied, distributed or passed on to any other person or published or reproduced directly or indirectly, in whole or in part, by any medium or in any form for any purpose. The information contained in this presentation must be kept confidential and must not be used for any other purpose. Neither this presentation nor any copy of it nor the information contained in it may be taken or transmitted in or into the United States, Canada, Japan or Australia, or distributed, directly or indirectly, in or into the United States, Canada or Australia, or distributed or redistributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of United States, Canadian, Japanese or Australian securities laws. The distribution of this presentation in other jurisdictions may be restricted by law, and persons into whose possessions this presentation comes should inform themselves about, and observe, any such restrictions.This document and its contents are confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose, and it is intended for distribution in the United Kingdom only to and is directed only at: (i) persons who have professional experience in matters relating to investments falling within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) persons falling within Article 49(2)(a) to (d) of the Order; or (iii) to those persons to whom it can otherwise lawfully be distributed (all such persons together being referred to as “relevant persons”). This document must not be acted upon by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.The information in this presentation is given in confidence and the recipients of this presentation should not base any behaviour in relation to qualifying investments or relevant
Important Notice - Disclaimer
2
The information in this presentation is given in confidence and the recipients of this presentation should not base any behaviour in relation to qualifying investments or relevant products (as defined in Financial Services and Markets Act 2000 (as amended) (“FSMA”) and the Code of Market Conduct (made pursuant to FSMA) which would amount to market abuse for the purposes of FSMA on the information in this presentation until after the information has been made generally available. Nor should the recipient use the information in this presentation in any way which would constitute “market abuse”.This presentation has been prepared by, and is the sole responsibility of, the Company. The information set out herein has not been verified by the Company or any other person. No representation or warranty, express or implied, is or will be made by the Company or any of its affiliates, directors, officers or employees, or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this presentation and any reliance you place on them will be at your sole risk. Without prejudice to the foregoing, the Company, their advisors and their respective affiliates, directors, officers or employees do not and will not accept any liability whatsoever for any loss howsoever arising, directly or indirectly, from use of this presentation or its contents or otherwise arising in connection therewith. The Company’s securities have not been nor will they be registered under the United States Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States except to qualified institutional buyers (as defined in Rule 144A) in reliance on Rule 144A or another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Company’s securities have not been nor will they be registered under the applicable securities laws of any state or jurisdiction of Australia, Canada or Japan and, subject to certain exceptions, may not be offered or sold within Australia, Canada or Japan or to or for the benefit of any national, resident or citizen of Australia, Canada or Japan.Certain statements in this presentation constitute “forward-looking statements”. These statements, which contain the words “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, reflect the Directors’ beliefs and expectations and are subject to risks and uncertainties that may cause actual results to differ materially. These risks and uncertainties include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the management of the Company. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. As a result, you are cautioned not to place undue reliance on such forward-looking statements. The Company and their advisors and each of their respective members, directors, officers and employees disclaim any obligation to update the Company’s view of such risks and uncertainties or to publicly announce the result of any revision to the forward-looking statements made herein, except where it would be required to do so under applicable law.
� EastPharma At A Glance
� Turkish Pharma Market
� Recent Developments in EastPharma
Agenda
3
� Company Outlook – EastPharma (EAST.LI)
� Financial Performance Overview – Consolidated Financial Statements 2007
� Appendix
EastPharma At A Glance
A leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical companyA leading branded generic pharmaceutical company
Consolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma MarketsConsolidation platform for Turkish & Eastern European Pharma Markets
4
Turkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed companyTurkey’s first fully institutionally managed company
ListedListedListedListedListedListedListedListed on on on on on on on on thethethethethethethethe LondonLondonLondonLondonLondonLondonLondonLondon MainMainMainMainMainMainMainMain StockStockStockStockStockStockStockStock Exchange (GDR)Exchange (GDR)Exchange (GDR)Exchange (GDR)Exchange (GDR)Exchange (GDR)Exchange (GDR)Exchange (GDR)
Turkish Pharma Market
OTCOTC
TURKISH PHARMA MARKET
RxRx
Pa
rtia
lly R
eim
bu
rse
d Fu
lly R
eim
bu
rse
d
5
(m/s in unit: 6.5%)(m/s in unit: 6.5%)(m/s in TRY: 4.2%)(m/s in TRY: 4.2%)
Branded
Original
(m/s in (m/s in unitsunits: 93.5%): 93.5%)(m/s in TRY: 95.8%)(m/s in TRY: 95.8%)
BrandedGenerics
BrandedGenericsP
art
iall
y R
eim
bu
rse
d Fu
lly R
eim
bu
rse
dPure Generics (INN)
Branded
Original
Source : IMS Health
� Turkey will be the # 10 pharma market by 2010; (currently: #13)
� Market size: US$9bn in 2007 (ex-factory price – government discounts) (28% yoy growth)� Per capita (pharmaceuticals) spend in Turkey: US$103 in 2006 (ex-factory price – government discounts)
� US$846 in USA, US$121 in Poland (Source: IEIS (Pharmaceutical Industry Assosiation) in 2006)
� CAGR growth for the period 2006–10 estimated 13.2% (2002–06 was 22%) (per capita growth)
Turkish Pharma Market
($ per capita)2002200220022002----06 CAGR: 22.3%06 CAGR: 22.3%06 CAGR: 22.3%06 CAGR: 22.3%
6Source : IMS Health
2002200220022002----06 CAGR: 22.3%06 CAGR: 22.3%06 CAGR: 22.3%06 CAGR: 22.3%
EastPharmaEastPharmaEastPharmaEastPharma isisisis thethethethe 5thththth largestlargestlargestlargest playerplayerplayerplayer inininin thethethethe TurkishTurkishTurkishTurkish PharmaceuticalPharmaceuticalPharmaceuticalPharmaceutical MarketMarketMarketMarket in terms of units
Turkish Pharma Market
ULAGAY5.3%
EASTPHARMA5.1%
SANOFI - AVENTIS4.3%
NOVARTIS 4.2% ECZACIBASI
- ZENVITA 4.1%
GLAXOSMITHKLINE 3.4%
YOY Growth in Units:
� Market: 8.3%
� EastPharma: 16.4%
7
Source: IMS Health (12M’ 07)ABDI IBRAHIM 9.2%
BAYER7.6%
BILIM6.9%
OTHERS 49.9%
YOY Growth in US$:
� Market: 28.1%
� EastPharma: 36.6%
Turkish Pharma Market
17,7%
29,0%33,3% 32,7%
28,1%25,8%
94,2%
-5,1%
44,8%
36,6%
0,0%
20,0%
40,0%
60,0%
80,0%
100,0%
Quarterly Market Growth (US$)
Market YOY Change
EP YOY Change
24,6%18,7%
14,5%8,6%
16,3%
33,2%
77,6%
-17,6%
18,6%25,7%
-20,0%
0,0%
20,0%
40,0%
60,0%
80,0%
100,0%
1Q' 07 2Q' 07 3Q' 07 4Q' 07 FY
Quarterly Market Growth (TRY)
Market YOY Change
EP YOY Change
8Source: IMS
-20,0%
1Q' 07 2Q' 07 3Q' 07 4Q' 07 FY
-40,0%
-20,0%
10,4%
2,5%
10,3% 10,0%8,3%
21,2%
39,8%
-7,1%
11,8%16,4%
-10,0%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
1Q' 07 2Q' 07 3Q' 07 4Q' 07 FY
Quarterly Market Growth (units)
Market YOY Change
EP YOY Change
Conclusion:
� EP performed better than the market in 07, in
terms of US$, YTL and units
� Slowdown in sales started in 3Q, but recovered in
4Q.
� Weakest month (US$): September
� Strongest month (US$): May
January – June 2007
� Sales incentive system: based on volume sales
� Implementation started in January
� Acquisitions:
� Saba Pharmaceuticals
� New Rep Offices:
� Georgia
Recent Developments at EastPharma
June – December 2007
� Term sheet signed
� Introduction of new sales structure
� New sales incentive system: based on
profitability
� Restructuring started in September
� Sales slow down in 3Q due to sales &
9
� Construction of Cerkezkoy and Kosekoy started
� Headquarters in Levent sold
marketing restructuring
� Implementation started in December
� New Rep Offices:
� Russia
� Ongoing Reorganization:
� Resignation of COO
� Successful transition to new headquarters
� Listed on LSE (GDR)
EastPharmaEastPharmaEastPharmaEastPharma isisisis thethethethe 5thththth largestlargestlargestlargest playerplayerplayerplayer inininin thethethethe TurkishTurkishTurkishTurkish PharmaceuticalPharmaceuticalPharmaceuticalPharmaceutical MarketMarketMarketMarket in terms of units
Turkish Pharma Market – March 2008
January – March 2008
� Asset purchase and in-licensing agreement with
Roche for sixteen products
� New Rep Offices:
� Uzbekistan in January
� Australia&New Zealand in February
� New Management appointments:EASTPHARMA
4.9%
NOVARTIS 4.3%
ECZACIBASI-ZENTIVA
3.9%
SANOFI-AVENTIS3.7%
GLAXOSMITHKLINE3.6%
10Source: IMS Health (3M’ 08)
� New Management appointments:
� Ms. Elif Elkin as Head of Marketing & Sales
� Dr. Tambay Taskin as R&D Director
� Ms. Tuba Koseoglu Okcu as Organizational
Development Executive Vice President
� Mr. Oguz Kesler as Executive Vice
President incharge of Business
Development and Exports
� Promotional activities for Deva’s 50th anniversary
ABDI IBRAHIM 8.3%
BAYER7.7%
BILIM7.5%
ULAGAY5.6%
4.9%
OTHERS 50.7%
STRATEGY
Operational TurnaroundOperational TurnaroundOperational TurnaroundOperational Turnaround�Increase market share & profitablity
– EastPharma market share in units: 5.1% in 12M’ 07; (4.7% in 12M’ 06)– Expansion / restructuring of the sales force with a new sales incentive system– Expansion of manufacturing capacity– Introduction of New Products with higher margins
� Targeting growth in new cardiovascular and other higher margin products
EastPharma Strategy: Long Term Value Creation
12
� Targeting growth in new cardiovascular and other higher margin products � Increasing Portfolio diversification
Financial TurnaroundFinancial TurnaroundFinancial TurnaroundFinancial Turnaround� Restructuring led by new management
– Disposal of noncore assets for proceeds of ~US$100mn – Customer- and product-driven agressive strategy– Cost savings initiatives
EastPharma Turkey
Turkey
JV’s, product acquisition, licensing and in-
licensing deals and acquisitions
CEEMEA
Existing Turkish Business Emerging Pharmaceutical Markets1 2
EastPharma Strategy: Geographic Expansion
Regulated Markets
Partnerships
3
North
AmericaWestern
Europe
13
– Focus on existing portfolio
– New product launches
– Turkish market consolidation
licensing deals and acquisitions
– Identify targets: Medium and large cap
companies
Organic Growth
– Expansion of EastPharma operations
• Georgia, Russia, Ukraine and Uzbekistan
– Export to regulated
markets
– Contract manufacturing
Strong Marketing Capabilities
14
Former Organisation:Former Organisation:Former Organisation:Former Organisation:� Strong sales and marketing organisation
� 15 regions in Turkey with 23 offices� 864 representatives:
� 6 groups of medical representatives� 1 group of pharmacy representatives
� 89 regional chief and managers As of January 2008. Excludes sales force presence in Georgia and Azerbaijan.New Organisation:New Organisation:New Organisation:New Organisation:� Efficient and profit orriented sales and marketing force
� 18 regions in Turkey with 23 offices � 747 representatives:
� 8 groups of medical representatives � 84 regional managers
Acquisitions: SABA PHARMACEUTICALS
Synergies CreatedSynergies CreatedSynergies CreatedSynergies Created1. Broadened Sales Team
� Sales Force increased from 60 to 140 people� Increased # of Regional Managers from 11 to 18� Increased # of doctors visited from 7,300 to 21,000� Increased # of pharmacists visited from 2,200 to 7,400
2. Larger Product Portfolio
15
2. Larger Product Portfolio
� Actively promoted products increased from 2 to 5 products � Application undertaken for Dentamax, an antibiotic registered by Deva, to allow SABA sales
representatives to sell the product , started selling in January 20083. Optimization of Operational Processes
� Introduced new sales incentive system� Transfer of manufacturing Saba's products to EastPharma's facilites has lowered costs
Acquisitions: SABA PHARMACEUTICALS
Attractive Valuation
� Purchased for US$ 14 mn
� 2006 Sales (unaudited): US$ 7 mn
� 2007 Sales (unaudited): US$ 12 mn
1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales
16
Financial Turnaround
� Net profit improved +388% from 2006 in US$ terms v loss in 2005
1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales1x 07E Sales
Regional Growth
Georgia Deva Rep. Office:
Address: Shio Mgvimeli № 1 B Vera, TBİLİSİ, GEORGIA PK. 0179
Baku / Azerbaijan Office:
44444444 reprepreprepreprepreprep........ offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: offices in the former Soviet Union: Georgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and UzbekistanGeorgia, Moscow (Russia), Azerbaijan and Uzbekistan
17
Baku / Azerbaijan Office:
Address: Istiklaliye Sok No: 31 Baku / AZERBAIJAN
Uzbekistan Deva Office:
Address: Deva Rep. Office Yusuf Hachacip Sok. No. 37 Taskent / UZBEKISTAN
Moscow / Russia Deva Office:
Address: Russian Federation, 109316 Moscow, Ostapovsky Proezd 5, Stroyenie 1, Office 811
Australia & New Zealand Sales Office:
Address: 3 Cliff Wilson Street Wanaka New Zealand
Enlargement of Product Portfolio
MarchMarchMarchMarchMarchMarchMarchMarch 08, 08, 08, 08, 08, 08, 08, 08, EastPharmaEastPharmaEastPharmaEastPharmaEastPharmaEastPharmaEastPharmaEastPharma completedcompletedcompletedcompletedcompletedcompletedcompletedcompleted an Asset an Asset an Asset an Asset an Asset an Asset an Asset an Asset PurchasePurchasePurchasePurchasePurchasePurchasePurchasePurchase AgreementAgreementAgreementAgreementAgreementAgreementAgreementAgreement & & & & & & & & InInInInInInInIn--------llllllllicenicenicenicenicenicenicenicensingsingsingsingsingsingsingsing and and and and and and and and SupplySupplySupplySupplySupplySupplySupplySupply AgreementAgreementAgreementAgreementAgreementAgreementAgreementAgreement withwithwithwithwithwithwithwith F.F.F.F.F.F.F.F.HoffmannHoffmannHoffmannHoffmannHoffmannHoffmannHoffmannHoffmann--------La La La La La La La La RocheRocheRocheRocheRocheRocheRocheRoche
Total revenues of products and licenses being acquired:
� Revenues of approx US$ 100mn in 2007
Successful completion of this transaction will provide:
� Purchase of 8 complementary products plus licenses for 8 products, all rights and registrations for Turkey. One of these products includes export rights to Russia and all CIS countries
18
EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:EastPharma expected to become:
Further details of this transaction are subject to a confidentiality agreement
�� 7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously7th largest player in revenue terms in Turkey v. 11th previously�� 3rd largest player in 3rd largest player in 3rd largest player in 3rd largest player in 3rd largest player in 3rd largest player in 3rd largest player in 3rd largest player in TurkeyTurkeyTurkeyTurkeyTurkeyTurkeyTurkeyTurkey in in in in in in in in unitunitunitunitunitunitunitunit termstermstermstermstermstermstermsterms v. 5th previouslyv. 5th previouslyv. 5th previouslyv. 5th previouslyv. 5th previouslyv. 5th previouslyv. 5th previouslyv. 5th previously
Turkey. One of these products includes export rights to Russia and all CIS countries
� Increase EastPharma’s exposure in key therapeutic areas
Closing expected by end of May, subject only to approval of Competition Board
Sales ForceSales ForceSales ForceSales ForceSales ForceSales ForceSales ForceSales Force
EastPharma's Competitive Advantages
Strong Brand NameStrong Brand NameStrong Brand NameStrong Brand NameStrong Brand NameStrong Brand NameStrong Brand NameStrong Brand Name
HighHighHighHighHighHighHighHigh Market Market Market Market Market Market Market Market ShareShareShareShareShareShareShareShare
19
HighHighHighHighHighHighHighHigh Market Market Market Market Market Market Market Market ShareShareShareShareShareShareShareShare
Large Distribution NetworkLarge Distribution NetworkLarge Distribution NetworkLarge Distribution NetworkLarge Distribution NetworkLarge Distribution NetworkLarge Distribution NetworkLarge Distribution Network
Substantial Substantial Substantial Substantial Substantial Substantial Substantial Substantial ProductionProductionProductionProductionProductionProductionProductionProduction CapacityCapacityCapacityCapacityCapacityCapacityCapacityCapacity
Current Therapeutic Breakdown in Units
Anti-infectives
39%
Cardiovascular
System
4%
Respiratory
System
6%
Central Nervous
System
4%
Others
10%
20
(1) Includes inter-segment sales Source: IMS (12M ’07)
Alimentary &
Metabolism
15%
Musculo
Skeletal
22%
Respiratory
9%
Central
Nervous
System
21%
Gastro
18%
Anti-infectives
13%
Therapeutic Breakdown in Units in 2010
21
21%
Musculo-
Skeletal
21%
Cardio
18%
Company Estimates
EastPharma Market Share Growing
Market Share – UnitsMarket Share – Revenue
3.1% 3.0% 3.2%
3.4% 3.6%
3.4%
%3
%44.9% 4.7%
5.1% 4.9% 5.0% 4.9%
%4
%6
22
Note: Market share data for Human pharmaceuticals segment
Source: IMS Source: IMS
Rank Rank Rank Rank 6 6 6 6 6 6 6 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 Rank 12 Rank 12 Rank 12 Rank 12 12 12 12 12 11 10 911 10 911 10 911 10 9 10101010
%2
31/12/0531/12/0631/12/07 JAN' 08 FEB' 08 MAR' 08
%0
%2
31/12/0531/12/0631/12/07 JAN' 08 FEB' 08 MAR' 08
EastPharma: Leading Products’ Market Shares in Turkish Market
20%
24%
15%
11%
19% 22%
15%
9%
22% 24%
18%
9% 9%
25%
20%
14%
8% 8%
5%
10%
15%
20%
25%
30% M/S %
23
RankRankRankRank(1)(1)(1)(1) 1111 2222 4444 6 7
# of competitors# of competitors# of competitors# of competitors(1)(1)(1)(1) 9 8 11112 11110000 11113
Source: IMS
(1) As of 3M ‘08
0%
5%
Cefaks Amoklavin Deklarit Degastrol Devasid
2005 2006 2007 3M' 08 2005 2006 2007 3M' 08 2005 2006 2007 3M' 08 2005 2006 2007 3M' 08 2005 2006 2007 3M' 08
NA
Top Ten Selling EastPharma Products
Product INN Name
Net Sales
(12M’07)
($ in mn)
Net Sales
(1H’07)
($ in mn)
% of Total Net
Sales
(12M’07)
Market Share
%
(12M’07)
Therapeutic
Category
Originator
Brand Name
Cefaks Cefuroxim Axetil $23.8 $14.6 13% 22% Anti-infectivesZinnat &
Cefatin
AmoklavinAmoxicilline+
Clavulanic Acid$18.8 $11.9 11% 24% Anti-infectives Augmentin
Dikloron Diclofenac $10.5 $5.7 6% 42%Musculoskeletal
System Voltaren
Degastrol Lansoprazol $9.2 $6.0 5% 9%Alimentary &
Ogastro
24Source: IMS
Degastrol Lansoprazol $9.2 $6.0 5% 9%Alimentary &
MetabolismOgastro
Trio
Amoxicilline+
Clarithromycin+
Lansoprazole
$8.5 $4.8 5% 46%Alimentary &
Metabolism Helipak
Devasid Sultamicillin $7.6 $6.6 4% 9% Anti-infectives Duosid
Deklarit Clarithromycin $7.5 $5.9 4% 18% Anti-infectives Klacid
Tekfin Terbinafine $5.7 $4.0 3% 16%Dermatologic
AntifungalLamisil
Azitro Azitromycin $5.2 $3.9 3% 31% Anti-infectives Zithromax
Ciflosin Ciprofloxacin $5.2 $3.3 3% 16% Anti-infectives Ciproxin
EastPharma Product Launches – Introduced in 20072007 NEW 2007 NEW 2007 NEW 2007 NEW PRODUCTSPRODUCTSPRODUCTSPRODUCTSINTRODUCEDINTRODUCEDINTRODUCEDINTRODUCED MOLECULEMOLECULEMOLECULEMOLECULE THERAPEUTIC THERAPEUTIC THERAPEUTIC THERAPEUTIC CATEGORYCATEGORYCATEGORYCATEGORY ORIGINATOR ORIGINATOR ORIGINATOR ORIGINATOR BRAND NAMEBRAND NAMEBRAND NAMEBRAND NAME MoleculeMoleculeMoleculeMoleculeMarket SizeMarket SizeMarket SizeMarket Size2007 2007 2007 2007 (US$ mn)(US$ mn)(US$ mn)(US$ mn) THERAPEUTIC THERAPEUTIC THERAPEUTIC THERAPEUTIC CLASS CLASS CLASS CLASS TherapeuticTherapeuticTherapeuticTherapeuticClassClassClassClassMarket SizeMarket SizeMarket SizeMarket Size2007 2007 2007 2007 (US$ mn)(US$ mn)(US$ mn)(US$ mn)COLASTINCOLASTINCOLASTINCOLASTIN----LLLL ATORVASTATIN CARDIOVASCULAR SYSTEM LIPITOR-PFIZER 161STATINS (HMG-COA RED) 212PANDEV PANDEV PANDEV PANDEV PANTOPRAZOLE ALIMENTARY T.&METABOLISM PANTPAS-BAYER 61
ACID PUMPINHIBITORS 307LUXAT LUXAT LUXAT LUXAT MONTELUKAST RESPIRATORY SYSTEM SINGULAIR-MSD 76RESPIRATORY SYSTEM 77LOSAPRES PLUSLOSAPRES PLUSLOSAPRES PLUSLOSAPRES PLUS LOSARTAN + HCl CARDIOVASCULAR SYSTEM HYZAAR-MSD 49ANGIOTENS-II ANTAG. COMB 219NIMELIDNIMELIDNIMELIDNIMELID NIMESULIDE MUSCULO- SKELETAL SYSTEM MESULID-PFIZER 11
ANTIRHEUMATICS NON-S PLN 372TORADOL- NON-NARCOTIC
25
KETRODOLKETRODOLKETRODOLKETRODOL KETOROLAC NERVOUS SYSTEM TORADOL-ROCHE 2NON-NARCOTIC ANALGESICS 127CONIELCONIELCONIELCONIEL BENIDIPINE CARDIOVASCULAR SYSTEM CONIEL-KYOWA HAKKO 1
CALCIUM ANTAGONISTS PLAIN 102DOXAFIN DOXAFIN DOXAFIN DOXAFIN DESLORATADINE RESPIRATORYSYSTEM AERIUS-SCHERING PLOUGH 29ANTIHISTAMINES SYSTEMIC 86DEGRA DEGRA DEGRA DEGRA (SINGLE DOZE) SILDENAFIL G.U.SYSTEM & SEX HORMONES VIAGRA-PFIZER 0
ERECTILE DYSFUNCTION PRD 94MAGCAR MAGCAR MAGCAR MAGCAR MAGNESIUM CARBONATE + CALCIUM CARBONATE ALIMENTARY T.& METABOLISM RENNIE-ROCHE 7 PLAIN ANTACIDS 31TOTAL MARKETTOTAL MARKETTOTAL MARKETTOTAL MARKET 397397397397 1,6271,6271,6271,627
Source: IMS
Contribution of New Launches in terms of market shareMolecule Units TRY
LUXAT *
(Respiratory System) Montelukast 8.2% 7.6%
LOSAPRES PLUS *
(Cardiovascular System) Losartan+HCI 5.8% 5.6%
CONIEL **
(Cardiovascular System) Benidipine 2.0% 2.5%
NIMELID *
(Musculo-skeletal System) Nimesulide 9.2% 7.0%
DEVASID *
(Anti-infective) Sultamicillin 7.3% 9.9%
Market share achieved in last 14 months (since launch)
26Source: IMS, March 2008
* Considered in molecule market** Considered in ATC4. (Coniel has no competitor in the market.)
(Anti-infective) Sultamicillin 7.3% 9.9%
PANDEV *
(Alimentary T&Metabolism) Pantoprazole 11.1% 9.6%
COLASTIN-L *
(Cardiovascular System) Atorvastatin 3.7% 2.8%
DOXAFIN *
(Respiratory System) Desloratadine 4.4% 3.3%
MAGCAR *
(Alimentary T&Metabolism)
Magnesium Carbonate+
Calcium Carbonate 5.4% 5.3%
Market share achieved in last 8 months (since launch)
Market share achieved in last 3 months (since launch)
EastPharma Product Launches – Pending
2008 PRODUCTS2008 PRODUCTS2008 PRODUCTS2008 PRODUCTS MOLECULEMOLECULEMOLECULEMOLECULE THERAPEUTIC THERAPEUTIC THERAPEUTIC THERAPEUTIC CATEGORYCATEGORYCATEGORYCATEGORY ORIGINATORORIGINATORORIGINATORORIGINATORBRAND NAMEBRAND NAMEBRAND NAMEBRAND NAME MoleculeMoleculeMoleculeMoleculeMarket SizeMarket SizeMarket SizeMarket Size2007200720072007(US$ mn)(US$ mn)(US$ mn)(US$ mn) THERAPEUTIC CLASS THERAPEUTIC CLASS THERAPEUTIC CLASS THERAPEUTIC CLASS TherapeuticTherapeuticTherapeuticTherapeuticClassClassClassClassMarket SizeMarket SizeMarket SizeMarket Size2007 (US$ mn)2007 (US$ mn)2007 (US$ mn)2007 (US$ mn)CEFAKS 250CEFAKS 250CEFAKS 250CEFAKS 250(new form)
CEFUROXIMAXETIL SYSTEMIC ANTI-INFECTIVES CEFATIN-ROCHEZINNAT-GSK 151CEPHALOSPORINS ORAL 285CITREX CITREX CITREX CITREX (DROP) - (new form) CITALOPRAM NERVOUS SYSTEM CIPRAM-LUNDBECK 27
SSRI ANTIDEPRESSANTS 166GENTAMISINGENTAMISINGENTAMISINGENTAMISIN(new form) GENTAMYCIN SYSTEMIC ANTI-INFECTIVES GARAMICIN-SCHERING PLOUGH 4 AMINOGLYCOSIDES 7RESTELARESTELARESTELARESTELA RISPERIDONE NERVOUS SYSTEM RISPERDAL-JOHNSON&JOHNSON 61
ATIPICAL ANTIPSYCHOTICS 204CANDEXIL CANDEXIL CANDEXIL CANDEXIL CANDESARTAN CILEXETIL CARDIOVASCULAR SYSTEM ATACAND PLUS-ASTRAZENECA 56
ANGIOTENS-II ANTAGONIST 219FAMOTIDINE-AMP *
*
*
*
* NEOTAB AMPNEOTAB AMPNEOTAB AMPNEOTAB AMP(new form)
FAMOTIDINE-AMP LYOPH 20 MG 2 5 ML ALIMENTARY T.& METABOLISM FAMODIN- SANDOZ 14 H2 ANTAGONISTS 23MOTISMOTISMOTISMOTIS DOMPERIDONE ALIMENTARY T.& METABOLISM MOTILIUM-JANSSEN CILAG 4 GASTROPROKINETICS 29LEVOSIDLEVOSIDLEVOSIDLEVOSID LEVOFLOXACIN SYSTEMIC ANTI-INFECTIVES TAVANIC-AVENTIS 75ORAL FLUOROQUINOLONES 179ALEMAXALEMAXALEMAXALEMAX ALENDRONIC ACID MUSCULO-SKELETAL SYSTEM FOSAMAX-MSD 30
BISPHOSPH OSTEOPOROSIS 49ZELEFTZELEFTZELEFTZELEFT SERTRALINE NERVOUS SYSTEM LUSTRAL-PFIZER 30SSRI ANTIDEPRESSANTS 166MUKOSİSTMUKOSİSTMUKOSİSTMUKOSİST ACETYLCYSTEIN RESPIRATORY SYSTEM MUCOMYST - BMS 74 EXPECTORANS 93
TOTAL MARKETTOTAL MARKETTOTAL MARKETTOTAL MARKET 526526526526 1,4201,4201,4201,420
Company Data
* licenced
27Cefaks 250 included in reimbursement list in April 2008
Investing to Accomodate the Growth
3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters3x Larger Headquarters
28
� New Headquarters� Successfully moved as of October 1st, 2007
Investing to Accomodate Growth – Update on Factories
� New factories� Cerkezkoy: 3 Buildings
- Beta-lactam- Cephalosporin
- General Production
3x 3x 3x 3x 3x 3x 3x 3x LargerLargerLargerLargerLargerLargerLargerLarger ProductionProductionProductionProductionProductionProductionProductionProduction CapacityCapacityCapacityCapacityCapacityCapacityCapacityCapacity
29
� Kosekoy: 1 Building- Injectables
� Current capacity: 100mn units
� New production capacity: 350mn units
� FDA and EMEA approvals
Cerkezkoy
Kosekoy:
Investing to Accomodate Growth – Update on Factories
30
FINANCIAL FINANCIAL FINANCIAL FINANCIAL FINANCIAL FINANCIAL FINANCIAL FINANCIAL PERFORMANCE OVERVIEWPERFORMANCE OVERVIEW
� EastPharma established in November 2006, thus 12M’ 06 financial performance only inlcudes one month performance and not comperable to 12M ’07 financials
� Deva aquired in November’ 06
� Deva Holding fully consolidated in EastPharma financials
� Saba aquired in May ’07 and fully consolidated in EastPharma financials
EastPharma Consolidated Financial Results – 12M ’07
Net Net Net Net Net Net Net Net SalesSalesSalesSalesSalesSalesSalesSales improvedimprovedimprovedimprovedimprovedimprovedimprovedimproved viaviaviaviaviaviaviavia strongstrongstrongstrongstrongstrongstrongstrong Deva Deva Deva Deva Deva Deva Deva Deva SalesSalesSalesSalesSalesSalesSalesSales RevenuesRevenuesRevenuesRevenuesRevenuesRevenuesRevenuesRevenues: 59% : 59% : 59% : 59% : 59% : 59% : 59% : 59% yoyyoyyoyyoyyoyyoyyoyyoy increaseincreaseincreaseincreaseincreaseincreaseincreaseincrease
OneOneOneOneOneOneOneOne time time time time time time time time costscostscostscostscostscostscostscosts and EBITDA and EBITDA and EBITDA and EBITDA and EBITDA and EBITDA and EBITDA and EBITDA adjustmentsadjustmentsadjustmentsadjustmentsadjustmentsadjustmentsadjustmentsadjustments forforforforforforforfor thethethethethethethethe yearyearyearyearyearyearyearyear total US$19 total US$19 total US$19 total US$19 total US$19 total US$19 total US$19 total US$19 mnmnmnmnmnmnmnmn
32
Net Sales� 59% yoy increase in Deva
� Positive impact of new product launches
� New incentive system
� Contributions:
- Human Pharma Revenue: 87%
- API: 5%
- Veterinary Products: 5%
- Consumer Goods: 3%
$142,1
$172,7
$128,6
$204,6
$8,8
$212,8
$59,6
$118,5
$165,0
$212,8
2004 2005 2006 2007 2006 2007 3M'07 6M'07 9M'07 12M'07
EP consolidatedEP consolidatedEP consolidatedEP consolidated
Summary Consolidated Financials – EastPharma (IFRS, mn$)
DevaDevaDevaDeva
- Consumer Goods: 3%
$66,4
$85,3
$48,6
$95,3
$0,9
$94,6
$26,1
$55,5
$75,9
$94,6
2004 2005 2006 2007 2006 2007 3M'07 6M'07 9M'07 12M'07
EP consolidatedEP consolidatedEP consolidatedEP consolidatedGross Profit
� 96% yoy increase at Deva
� Relatively limited increase in COGS
� Targeting better margins with new
products
DevaDevaDevaDeva
33
Contribution of New Launches in value terms
CardiovascularCardiovascular segmentsegment shareshare increasedincreased fromfrom 3.7% in 3M’ 07 3.7% in 3M’ 07 toto 5.2% in 12M’075.2% in 12M’07
� Colastin included in reimbursement list in June’ 07
� Coniel included in reimbursement list in July’ 07
GastroGastro segmentsegment shareshare improvedimproved fromfrom 15% in 3M’ 07, 15% in 3M’ 07, toto 15.8% in 12M’ 07 15.8% in 12M’ 07
� Pandev included in reimbursement list in June’ 07
34
46,7%49,4%
46,6% 46,9% 46,0% 44,5%
Gross Profit and COGS Margin – EastPharma (IFRS)
Gross Profit Margin COGS Margin
53,3%50,6%
62,2%
53,4%56,2% 54,7% 54,0% 55,5%
EP consolidatedEP consolidatedEP consolidatedEP consolidated EP consolidatedEP consolidatedEP consolidatedEP consolidatedDevaDevaDevaDeva
AbilityAbilityAbilityAbilityAbilityAbilityAbilityAbility totototototototo be be be be be be be be moremoremoremoremoremoremoremore efficientefficientefficientefficientefficientefficientefficientefficient thanthanthanthanthanthanthanthan thethethethethethethethe competitioncompetitioncompetitioncompetitioncompetitioncompetitioncompetitioncompetitionwillwillwillwillwillwillwillwill bringbringbringbringbringbringbringbring us a us a us a us a us a us a us a us a competitivecompetitivecompetitivecompetitivecompetitivecompetitivecompetitivecompetitive advantageadvantageadvantageadvantageadvantageadvantageadvantageadvantage
DevaDevaDevaDeva
46,7%
37,8%
46,6%43,8%
46,9% 46,0% 44,5%
2004 2005 2006 2007 3M'07 6M '07 9M'07 12M'07 2004 2005 2006 2007 3M '07 6M '07 9M '07 12M '07
35
Marketing ExpensesGeneral
Administration Expenses
26,1%
31,7%
28,8%27,1%
28,8%
Research & Development Expenses
17,8%
12,8
EP consolidatedEP consolidatedEP consolidatedEP consolidated
Operating Margins – EastPharma (IFRS)
DevaDevaDevaDeva EP consolidatedEP consolidatedEP consolidatedEP consolidatedDevaDevaDevaDeva EP consolidatedEP consolidatedEP consolidatedEP consolidatedDevaDevaDevaDeva
24,0%
20,6%
21,4%
2004 2005 2006 2007 3M 6M 9M 12M
9,1%8,2%
12,2%
8,2%
6,8%
8,9%
12,8%
2004200520062007 3M 6M 9M 12M
36
Summary Consolidated Financials – EastPharma (IFRS, mn$)
EBITDA(1)
�Sales and Gross Margin improvements have a positive impact $24,0
$31,1
($9,2)
$33,5
$11,4
$21,7
$28,6$33,2
EP consolidatedEP consolidatedEP consolidatedEP consolidatedDevaDevaDevaDeva
(1) Earnings Before Interest, Taxation, Depreciation & Amortisation (Note: excludes other gains and losses and gain on monetary position)
($9,2)
2004 2005 2006 2007 3M'07 6M'07 9M'07 12M'07
Operational turnaround strategy
Focus on increased market share & profitability
– Expansion / restructuring of sales force with a new sales incentive system
– Expansion of manufacturing capacity
– Introduce new products with higher margins & increase portfolio diversification
37
Highlights on Saba Financials (mn$)
� 67% yoy increase in Net Sales: US$ 12mn
� Gross profit margin: 59%
FocusFocusFocusFocusFocusFocusFocusFocus on on on on on on on on nichenichenichenichenichenichenicheniche market and market and market and market and market and market and market and market and beingbeingbeingbeingbeingbeingbeingbeing competitivecompetitivecompetitivecompetitivecompetitivecompetitivecompetitivecompetitive: : : : : : : :
� Increase in operating expenses in line with sales team
� Net profit: US$ 0.53 mn
38
Normalized Consolidated Financials – EastPharma (IFRS, $)
For the year
ended
31 December
2007
17 August 2006
(inception date) to
31 December 2006
Normalized
Income
Statement
31 December 2007
Revenue 212.781.055 8.789.176 214.810.084
Cost of sales (118.180.612) (7.902.586) (113.251.762)
Gross profit 94.600.443 886.590 101.558.322
Operating expenses (91.490.567) (9.630.700) (85.227.779)
Investment revenue 7.387.650 446.735 5.358.621
Finance costs (21.142.973) (2.744.202) (7.141.909)
Other gains and losses (1.934.762) 74.780 3.740.121
*
Reorganization Adjustment Costs (US$, Thousand)
Retirement pay provision
39Source: Company Management
Other gains and losses (1.934.762) 74.780 3.740.121
Loss before tax (12.580.209) (10.966.797) 18.287.376
Current tax expense (2.205.014) (679.342) (2.205.014)
Deferred tax expense 2.736.355 2.153.824 (2.106.467)
Income tax expense 531.341 1.474.482 (4.311.481)
Net loss for the period (12.048.868) (9.492.315) 13.975.895
Attributable to:
Equity holders of the parent (9.305.503) (6.023.907) 10.793.772
Minority interest (2.743.365) (3.468.408) 3.182.123
(12.048.868) (9.492.315) 13.975.895
* Excludes costs relating to reorganization (US$18.89mn) and currency hedging (US$14.00mn)
Retirement pay provision
(restructuring of personnel) 7.041
Loss on disposal of property,
plant and equipment 3.172
Payment for environmental
liability 1.520
Provision for tax penalty 2.631
Interest received on sales with
deferred settlement terms 2.029
Fair value of put option liability 2.503
Total 18.896
IR Contact Details:
Idil Bora – IR Manager
Email : [email protected] / [email protected]
D. Phone : +90 212 6929326
Fax : +90 212 6970614
Address: Halkali Mah. Basin Ekspres Cad. 34303 No:1
Kucukcekmece - Istanbul
THANK YOU FOR YOUR INTERESTTHANK YOU FOR YOUR INTEREST
APPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIXAPPENDIX
EastPharma Shareholder StructureEastPharma Ltd.
(As of February, 2008)
Saba Pharmaceuticals
100.00% of A, B, C & D shares
EastPharma Ltd.
Deva Holding A.S.
EastPharma
Ltd.
Free
Float
C Shares: 94,33% 5,67%- Direct Control 82,25%- Indirect Control 12,08%
Gavea
Master
Fund Ltd.
3,8%
D. E. Shaw
Laminar
Portfolios
8,3%
Griffin
Funds;
2,4% Enso
Funds;
2,3%
Free Float;
(As of February, 2008)
42
95.50% of Founder shares
A Shares: 100,00% -- Direct Control 74,00%- Indirect Control 26,00%
B Shares: 92,00% 8,00%- Direct Control 72,00%- Indirect Control 20,00%
GEM
Funds,
61.63%
Free Float;
21,2%
Raffles
Associate
0,4%